INS and Hyperglycemia: Although metformin followed by the addition of a DPP-4 inhibitor, with a switch from the DPP-4 inhibitor to a GLP-1 receptor agonist or insulin therapy as required to maintain glycemic targets, is suggested as a suitable treatment of hyperglycemia secondary to pasireotide therapy, the efficacy of anti-hyperglycemic regimens needs to be further explored in a clinical trial in patients with Cushing’s disease.